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Human infection by Zika virus (ZIKV) during pregnancy can lead to
vertical transmission and fetal aberrations, including microcephaly.
Prophylactic administration of antibodies can diminish or prevent
ZIKV infection in animal models, but whether passive immunization
can protect nonhuman primates and their fetuses during pregnancy
has not been determined. Z004 and Z021 are neutralizing monoclo-
nal antibodies to domain III of the envelope (EDIII) of ZIKV. Together
the two antibodies protect nonpregnant macaques against infection
even after Fc modifications to prevent antibody-dependent en-
hancement (ADE) in vitro and extend their half-lives. Here we report
on prophylactic coadministration of the Fc-modified antibodies to
pregnant rhesus macaques challenged three times with ZIKV during
first and second trimester. The two antibodies did not entirely
eliminate maternal viremia but limited vertical transmission, pro-
tecting the fetus from neurologic damage. Thus, maternal passive
immunization with two antibodies to EDIII can shield primate
fetuses from the harmful effects of ZIKV.
Fc domain modifications | Zika virus | macaque pregnancy model |
antibody-dependent enhancement | congenital Zika syndrome
ZIKV is a mosquito-borne flavivirus that in humans is oftenasymptomatic but can manifest as febrile illness and rarely as
neurologic disease (1, 2). Although ZIKV was discovered in
1947, its devastating effects on fetal health were only recognized
during the 2015 outbreak in the Americas (3). ZIKV infection
during pregnancy can result in a range of birth defects that pre-
dominantly involve the central nervous system, including micro-
cephaly (4–6). The rate of adverse outcomes varies but can surpass
40% in some regions (7–10). Similar consequences are observed in
macaques, where experimental infection during gestation can lead
to fetal neuropathology and demise (11–13).
Although the path to approval is challenging due to the
waning epidemic, several ZIKV vaccine candidates have entered
clinical trials (14, 15). In preclinical settings, vaccine efficacy was
demonstrated in mice and macaques (16, 17), including mouse
and macaque pregnancy models (18–21). One of the potential
issues with vaccination is that active immunization regimens re-
quire time to induce protective immunity and therefore vacci-
nation after conception may be ineffective in preventing fetal
disease in the setting of an active outbreak. In addition, there is
concern about vaccine-mediated enhancement because features
of maternal antibodies that enhance ZIKV infection in vitro are
associated with an increased risk of human microcephaly and
other neurologic defects in humans and macaques (22). Thus,
there is a need to develop strategies to limit maternal and fetal
pathology that are rapid, effective, and safe.
Results
The combination of human IgG1 monoclonal antibodies Z004
and Z021 significantly reduces plasma viral loads and prevents
emergence of viral escape mutations in nonpregnant rhesus
macaques challenged with a superphysiologic dose of ZIKV
i.v. (105 plaque-forming units [PFU]) (23). Similar results were
obtained when the antibodies were modified to prevent
antibody-dependent enhancement (ADE) in vitro by mutations
that abrogate Fc-γ receptor engagement (GRLR; refs. 23 and 24).
Significance
Zika virus (ZIKV) infection during pregnancy can cause fetal
abnormalities. Vaccines against ZIKV are under development,
but because of potential safety concerns due to disease-
enhancing antibodies, and the time required by active im-
munization to induce protective antibodies, there is a need
to explore alternative strategies. Recombinant monoclonal
antibodies can be modified to prevent enhancement of in-
fection, and thus could be an efficacious and safe alternative
to vaccines to confer rapid protection. We show that pro-
phylactic administration of two engineered antibodies, Z004
and Z021, to pregnant macaques partially protects against
fetal neurologic damage and limits vertical transmission
of ZIKV.
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To evaluate the protective effect of these antibodies against
what is considered to be a more physiologic dose and route of
administration, we administered Z004GRLR + Z021GRLR to
macaques 24 h before s.c. inoculation with 103 PFU of ZIKV
(Fig. 1A) (25, 26). In untreated controls, plasma viremia peaked
on days 4 to 5 after infection, reaching between 105 and 107 RNA
copies/mL (n = 4; black in Fig. 1B). In contrast, plasma viremia
was undetectable in three out of six antibody-treated macaques,
and it was lower and delayed in the remaining three animals
(green in Fig. 1 B–D). Since ZIKV can be detected in macaque
tissues even when absent from plasma (13, 27), we measured
viral RNA in a panel of 17 tissues (Fig. 2). Viral RNA was evi-
dent in multiple tissues in control animals as well as in the three
animals that showed low and delayed viremia after infection
(Fig. 2 A, Right). In contrast, viral RNA was low or undetectable
in tissues from macaques with no detectable plasma viremia (Fig.
2 A, Left and Fig. 2B). Thus, prophylactic administration of
Z004GRLR + Z021GRLR prevents or reduces viral accumulation
in plasma and tissues upon low-dose ZIKV challenge.
The half-life of Z004 and Z021 can be extended by altering the
antibody’s Fc domain (LS mutation; refs. 28 and 29) without
altering ZIKV neutralizing activity in vitro or in vivo (23). To
determine whether Z004GRLR/LS + Z021GRLR/LS remains effi-
cacious in macaques, we administered the combination before
low-dose s.c. challenge with ZIKV. Z004GRLR/LS + Z021GRLR/LS
showed extended half-lives and their levels in plasma remained
more than 4 logs above the in vitro inhibitory concentration
throughout the monitoring period (SI Appendix, Fig. S1). The
treatment prevented plasma viremia in two of six macaques; one
macaque had a single episode of low-level viremia (less than
103 viral RNA copies/mL on day 2 postinfection), and the
remaining three had lower and delayed viral loads (orange in Fig.
1 B–D) compared to untreated controls. The macaques that
developed plasma viremia after administration of Z004GRLR +
Z021GRLR or Z004GRLR/LS + Z021GRLR/LS had viruses with
mutations in the envelope domain III (EDIII) region: T309A,
T309A/V330L, T309I/V330L, and V330L (Fig. 3 A–C). To de-
termine whether these substitutions confer resistance to the
antibodies, we produced reporter virus particles (RVPs; ref. 30)
with these mutations and evaluated them for sensitivity to the
two antibodies (Fig. 3D). Both antibodies retained potency
against RVPs containing the V330L mutation, which was also
found in untreated control animals (Fig. 3A). This mutation is
located outside the epitope of either antibody (Fig. 3B). Al-
though T309 is in the epitope of both antibodies (Fig. 3 B and C),
its mutations affected the potency of Z021 alone. Since T309
mutations did not alter ZIKV sensitivity to the combination of
antibodies in vitro, they are unlikely to represent virus escape
(Fig. 3D). Consistent with these findings, the mutations involved
residues other than those altered in the viruses emerging from
macaques treated with the individual antibodies (E393 and K394
with Z004, and T335 with Z021; ref. 23 and SI Appendix, Fig. S2).
We conclude that Z004GRLR/LS + Z021GRLR/LS prevents emer-
gence of viral escape variants found with monotherapy (ref. 23
and SI Appendix, Fig. S2) and are as efficacious as their GRLR
counterparts against ZIKV in macaques.
ZIKV infection of pregnant macaques is associated with fetal
demise and neuropathology (11–13). To evaluate the effect of
anti-ZIKV antibodies on fetal development and health in preg-
nant primates, we performed timed breeding experiments and
challenged the dams three times with 103 PFU of ZIKV s.c. on
gestational days (GDs) GD30, GD60, and GD90, which corre-
spond to first and second trimester (normal gestation of rhesus
macaques is ∼165 d) (21). Macaques in the treatment group
received i.v. infusions of Z004GRLR/LS + Z021GRLR/LS antibodies
24 h before each virus challenge (Fig. 4A). Both dam and fetus
were closely monitored; animals were killed near the end of
gestation for detailed tissue analysis (SI Appendix, Tables S1 and
S2). During this whole observation period, human IgG plasma
levels remained 3 logs or higher than the in vitro inhibitory
concentration (Materials and Methods and SI Appendix, Fig. S3).
Untreated macaques developed plasma viremia that peaked
between days 2 and 5 after the first ZIKV inoculation (Fig. 4 B,
Left and ref. 21). In contrast, out of the eight antibody-treated
dams, three had no detectable viremia, while four other animals
had delayed peak viremia on days 7 (n = 1) or 21 (n = 3) after the
first inoculation, and a fifth developed peak viremia on GD90, 30
Fig. 1. Administration of Z004GRLR/LS + Z021GRLR/LS antibodies reduces
magnitude and duration of ZIKV viremia in nonpregnant rhesus macaques.
(A) Schematic of the experiment. Macaques were administered Fc-modified
human monoclonal antibodies Z004 and Z021 1 d prior to s.c. challenge with
103 PFU of Puerto Rican Zika virus (ZIKV-PR). (B) Antibody treatment alters
plasma viral loads. Macaques received either the GRLR version of the anti-
bodies (green), the GRLR/LS version (orange), or were left untreated (black).
Shown are plasma ZIKV RNA levels over time as determined by qRT-PCR. The x
axis is set at the limit of detection (2.3 log RNA copies/mL). (C) Peak plasma
viral RNA levels are decreased in antibody-treated macaques (based on B). In
gray is the peak viral load of both Z004GRLR + Z021GRLR and Z004GRLR/LS +
Z021GRLR/LS groups combined. The dotted line represents the limit of detection
of the assay and samples with undetectable ZIKV were arbitrarily assigned a
value equal to half of the limit of detection. (D) Peak plasma viremia is delayed
in antibody-treated macaques (based on B). Bars in C and D represent the
mean; the P values were determined with the Mann–Whitney U test.
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days after the second ZIKV inoculation (Fig. 4 B, Right). In
addition, viremia was significantly lower and of shorter duration
in antibody-treated dams (Fig. 4 B–F). Fetal death (i.e., no
heartbeat on ultrasound) was detected in two control animals
(C03 and C07) on GD35 and GD60 (i.e., 5 and 30 d after the first
ZIKV inoculation), with detectable viral RNA in placental and
fetal tissues (21). Fetal death was observed on GD51 in one of
the antibody-treated macaques (AB02). This occurred 1 wk after
undergoing routine amniocentesis and was coincident with a
sudden spike of maternal viremia (>105 RNA copies/mL; Fig.
4B) and ZIKV in the amniotic fluid (104 RNA copies/mL) and
placental-amniotic tissues (>104 RNA copies/g tissue). In the
antibody-treated pregnant dams, mutations in the EDIII region of
the emerging viruses were similar to the previously observed mu-
tations that did not alter sensitivity to the antibodies in combination
and therefore are unlikely to represent escape (Fig. 3 and SI Ap-
pendix, Fig. S4). We conclude that the Z004GRLR/LS + Z021GRLR/LS
combination prevents or significantly reduces maternal viral loads
during pregnancy.
Amniocentesis was performed regularly to monitor potential
ZIKV transmission to the placental-fetal compartment. Six
control animals (50%) had detectable ZIKV RNA in at least one
amniotic fluid sample. In contrast, except for antibody-treated
animal AB02 at time of fetal death, none of the other antibody-
treated animals had detectable vRNA in amniotic fluid samples
(SI Appendix, Fig. S5). Since vertical transmission of ZIKV can
cause congenital Zika syndrome (CZS), we examined the fetuses
in the pregnancies that reached term. Fetal body, placenta, brain,
and other fetal organ weights were indistinguishable between
controls and treatment groups (SI Appendix, Fig. S6). In 9 of the
Fig. 2. Zika viral RNA levels in tissues are decreased in antibody-treated male macaques. (A) Viral RNA was measured in a panel of tissues obtained at time of
killing (days 26 to 29 postinfection). Values represent log10 of viral RNA copies per gram of tissue, as determined by qRT-PCR. Data are represented as mean ±
SD of triplicate measurements. In green are macaques treated with Z004GRLR + Z021GRLR and in black are untreated controls. Antibody-treated macaques are
arranged according to whether they had detectable plasma viremia at any time point after ZIKV inoculation. (B) Shown for each macaque is the number of
tissues with detectable viral RNA. Bars represent the mean; the P values were determined with the Mann–Whitney U test.
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10 control untreated fetuses that made it to the end of gestation,
ZIKV RNA was detected in at least 1 of the 17 examined tissues.
These include the maternal–fetal interface (MFI), lymphoid,
cardiopulmonary, urinary, gastrointestinal, and central nervous
systems, and the skin (average of 6 ZIKV RNA positive tissues
per fetus; Fig. 5A). In contrast, viral RNA was undetectable in
the same fetal tissues from the seven antibody-treated animals
that reached end of gestation (Fig. 5A). Moreover, fetuses that
received antibodies had less brain pathology overall, as only 1
out of 7 fetuses (14%) had a brain pathology score of moderate
(score of 3) or above, in contrast to 4/10 (40%) of the control
fetuses (ref. 21, Fig. 5B, and SI Appendix, Fig. S7 and Table S3).
Though its dam had no detectable viremia, it is possible that the
moderate brain pathology score in one antibody-treated fetus
(AB08-F) reflects earlier infection that was cleared by the time
the fetus was harvested. Pathology scores of placenta and am-
nion were not significantly different between groups (SI Appen-
dix, Fig. S7 and Table S3). Finally, there was no correlation
between maternal viremia and pathology scores; while aviremic
animal AB05 had normal fetus and placenta, macaque AB07 was
also aviremic but its fetus and placenta showed mild to moderate
pathology scores, respectively; in contrast, the fetus of animal
AB06, which had higher than 104 RNA copies/mL at peak ma-
ternal viremia, had normal brain findings but moderate placental
pathology (Fig. 5B and SI Appendix, Fig. S7). We conclude that
maternal administration of Z004GRGR/LS + Z021GRLR/LS limits
vertical transmission and fetal brain damage by ZIKV.
Discussion
Recombinant antibodies represent an alternative to vaccines for
at-risk populations. Passive immunization reduces or prevents
ZIKV infection in nonpregnant rodents and macaques (23, 25,
26, 31, 32). In addition, antibodies diminish ZIKV viral burden in
the placenta and fetal organs, and also reduce fetal demise in mouse
pregnancy models (33–35). Some of these ZIKV mouse pregnancy
models reproduce features of the human disease, including brain
Fig. 3. Mutations in Zika virus emerging in plasma from antibody-treated nonpregnant macaques remain sensitive to Z004 and Z021. (A) Summary of the
amino acid changing mutations in the EDIII of ZIKV. The virus EDIII region recognized by Z004 and Z021 was amplified and sequenced at peak plasma viremia.
Shown is a graphic summary of the identifiedmutations. Note that V330L was also detected in one untreated macaque.Wewere unable to amplify the EDIII from
one sample with RNA copies/mL below 103. (B) The mutations are mapped on the structure of the sE dimer of ZIKV (PDB ID: 5JHM). The structures of the Z004-
related antibody Z006 (PDB ID:5VIG) and of Z021 (PDB ID:6DFI) in complex with the EDIII of ZIKV are structurally aligned to the sE dimer to show the location of
residues T309 and V330 relative to the binding sites of the antibodies. The ZIKV EDIII from the Z006-EDIII and Z021-EDIII structures are omitted for clarity. (C) The
epitopes of ZIKV EDIII recognized by the Z004-related antibody Z006 (in red), by Z021 (in blue), and by both antibodies (in purple) are shown. Residue T309 is
highlighted. (D) Z004, Z021, and the two antibodies together (Z004 + Z021) neutralize RVPs corresponding to ZIKV wild-type sequence or ZIKV mutated at the
indicated residues. For Z004 + Z021, each of the antibodies is added at the indicated concentration (e.g., 10 ng/mL contains 10 ng/mL of Z004 plus 10 ng/mL of
Z021). Data are represented as mean ± SD of triplicates and a representative of two experiments is plotted. Values are relative to isotype control.
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pathology (4–6). However, mice are not natural hosts for ZIKV,
and the development of pathology typically requires an impaired
immune system. As opposed to immunocompetent rodents,
macaques can be infected readily with ZIKV and their preg-
nancies are anatomically and physiologically far more similar to
humans (36). Whether antibodies can prevent fetal disease in
macaques had not been determined. Our experiments show that
the combination of two ZIKV neutralizing human monoclonal
antibodies is sufficient to thwart or significantly reduce maternal
viremia, prevent virus accumulation in fetal tissues, and reduce
fetal pathology following repeated ZIKV challenge in macaques.
The results have many similarities, but also some differences, with
results obtained using the ZIKV DNA vaccine VRC5283 that was
tested in the same animal model of congenital ZIKV disease (21).
VRC5283 is a DNA vaccine that produces subviral particles
with premembrane, membrane, and envelope proteins, is immu-
nogenic in a phase 1 clinical trial, and is currently being evaluated
in a phase 2/2b (17, 37, 38). In the macaque pregnancy experiment
with similar design to the present study, two doses of vaccine prior
to ZIKV inoculation significantly reduced maternal viremia when
animals were challenged between 4 d to 1 y after the second im-
munization (21). Viremia was undetectable in 5 of 13 animals
(38%), a rate of protection comparable to the current antibody
treatment study (37.5%; n = 8). In addition, in the ZIKV DNA
vaccine study, the presence or absence of detectable viremia in
vaccinated dams correlated with the titer of neutralizing antibody
responses at the time of the first ZIKV challenge (i.e., animals
with antibody titers above a threshold had no detectable viremia).
For vaccinated animals with detectable viremia, the reduced vi-
remia was always early (peak viremia ≤5 d after ZIKV in-
oculation), and short in duration (≤14 d after the first ZIKV
challenge), consistent with the observed rapid augmentation of
antiviral antibody and T cell-mediated immune responses in vac-
cinated animals after challenge (21).
Fig. 4. Administration of Z004GRLR/LS + Z021GRLR/LS prevents or reduces ZIKV viral loads in pregnant macaques. (A) Schematic of the experiment. Pregnant
macaques were administered Z004GRLR/LS + Z021GRLR/LS antibodies 1 d prior to s.c. challenge with 103 PFU of ZIKV on each of GD30, GD60, and GD90. PR is
Puerto Rican and BR is Brazilian ZIKV. Blood samples were obtained throughout the pregnancy. (B) Antibody treatment alters plasma viral loads. Macaques
were either untreated (Left) or treated with Z004GRLR/LS + Z021GRLR/LS (Right). Shown are plasma ZIKV RNA levels over time. LOD, limit of detection. Asterisks
indicate animals with early fetal death. (C) Peak plasma viral RNA levels are decreased in antibody-treated macaques (based on B). The dotted line represents
the LOD of the assay where samples with undetectable ZIKV were arbitrarily assigned a value equal to the LOD. (D) Peak plasma viremia is delayed in treated
animals. (E) Overall plasma viral loads are decreased in treated macaques. (F) Duration of viremia is reduced in animals that received antibodies. Bars in C–F
represent the mean; the P values were determined with the Mann–Whitney U test.
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In the passive immunization studies with Z004 and Z021,
antibodies failed to prevent viremia when nonpregnant ma-
caques were inoculated i.v. with a high dose of virus (105 PFU;
ref. 23). In contrast, we achieved an overall 40% protection from
detectable viremia in 20 animals infected with a more moderate
dose of 103 PFU of ZIKV administered s.c. (5 protected out of
12 nonpregnant macaques and 3 protected out of 8 pregnant
dams). This dose is still higher than the typical dose received
from a mosquito bite, which in laboratory experiments was
∼30 PFU for both the ZIKV isolates used in this study (39).
This protection was observed irrespective of Fc domain mutations
that modify Fc receptor binding. Neutralizing antibody levels
on day of challenge were similar between antibody-treated ani-
mals with or without detectable viremia and were ≥3 logs higher
than the in vitro inhibitory concentration. However, animals
showing low levels and even no ZIKV in plasma had detectable
viral RNA in tissues. This indicates that in some animals the virus
was able to spread despite high levels of the neutralizing anti-
bodies in serum. These results contrast with earlier reports of
sterilizing protection by antibodies under similar virus challenge
conditions (s.c. inoculation with 103 PFU). However, sampling was
less frequent and over a shorter time period in those studies and
therefore transient or delayed viremia may have gone undetected
(25, 26). The delay in viremia in the current study, despite high
levels of the two neutralizing antibodies in the circulation, suggests
that following moderate- to high-dose ZIKV inoculation, virus can
still reach tissues and initiate replication, either because in some
tissues antibodies did not penetrate sufficiently, or because certain
cell types became infected via mechanisms (e.g., via different cell
receptors) that are insufficiently captured in the standard in vitro
neutralization assays. The delayed peak viremia (7 to 60 d post-
inoculation) in the pregnant dams likely reflects burst of virus
replication in such reservoirs, which then triggered the develop-
ment of active immune responses. The observation of early fetal
losses in two control fetuses and one antibody-treated dam, with
high levels of virus in fetal or placental tissues, and rapid disap-
pearance of plasma viremia following fetectomy, indicates the
fetal-placental compartment as a possible reservoir that is shielded
from antiviral immune responses. The observation of delayed vi-
remia also in antibody-treated nonpregnant macaques suggests the
existence of additional reservoirs, of which the identification will
improve our knowledge of ZIKV pathogenesis and our ability to
develop intervention strategies.
For the unimmunized control pregnancy arm, we previously
reported a positive association between fetal pathology scores
and prolonged maternal viremia (21). In contrast, although
overall pathology scores were reduced compared to the control
arm, some fetuses in the active or passive immunization arms
had demonstrable fetal or placental pathology despite having no
detectable viral RNA in tissues or circulation. While small group
sizes are an inherent limiting factor, several other factors may
contribute to this finding. As mentioned earlier, the absence of
viral RNA at time of killing does not exclude the possibility of
earlier ZIKV replication followed by viral clearance. In addition,
independent of ZIKV, the frequent amniocentesis procedures
may also be a confounding factor that can directly affect amnio-
placental pathology scores and ultimately fetal brain development
(reviewed in ref. 40). Finally, although representative specimens
were sampled to our best ability, pathological lesions and viral
RNAmay be localized temporally and spatially, rather than evenly
distributed.
Despite these study limitations, and despite differences in the
kinetics of viremia, early versus delayed viremia in vaccinated
versus antibody-treated pregnant dams, the reduced maternal
viremia and associated improved fetal outcomes were similar in
the two studies (21). Thus, the VRC5283 vaccine and the
Z004GRLR/LS + Z021GRLR/LS antibodies are comparably effica-
cious vis-à-vis fetal protection, with each strategy having their in-
trinsic advantages and limitations in terms of speed of induction,
potential for enhancement, and durability of protective immunity.
Dengue is a flavivirus closely related to ZIKV. Dengue virus
reinfection can lead to antibody-enhanced disease by a mecha-
nism that is associated with serologic cross-reactivity between
different dengue serotypes and prior dengue infection has been
associated with increased risk of Zika microcephaly (41–44).
Antibodies to dengue also cross-react with ZIKV and experi-
ments in mice and with human placental explants have shown
that ZIKV infection can be enhanced by antibodies in these
systems (45–48). Conversely, antibodies to ZIKV that are ma-
ternally acquired cause more severe disease in mice infected with
dengue (49). Finally, features of the antibodies that increase
ZIKV infection in in vitro ADE assays correlate with an
Fig. 5. Protection of macaque fetuses by Z004GRLR/LS + Z021GRLR/LS. (A) With exception of AB02-F (i.e., the fetus of dam AB02), ZIKV RNA is undetectable in
placental and fetal tissues from antibody-treated dams. Viral RNAwas measured in a panel of 17 fetal tissues and three fluids harvested at pregnancy termination.
LN, lymph node; CSF, cerebrospinal fluid; AF, amniotic fluid; GI, gastrointestinal; and CNS, central nervous system. * indicates the two control animals and one
antibody-treated animal with early fetal death. (B) Lower fetal brain pathology in animals receiving Z004GRLR/LS + Z021GRLR/LS. Triangles indicate fetuses whose
dams had no detectable plasma viremia. Horizontal lines represent mean values and the P value was determined with the Mann–Whitney U test. Pregnancies that
terminated prematurely (GD60 or earlier) were omitted from this panel. Pathology scores of fetal tissues are summarized in SI Appendix, Fig. S7.
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enhanced risk of Zika microcephaly in humans and brain pa-
thology in macaque (22). Thus, the potential for enhancement is
a safety concern for ZIKV vaccine development that clinical
trials need to address. Since monoclonal antibodies that are Fc
modified to prevent ADE can shield against ZIKV infection and
fetal damage, they represent a potentially safe and efficacious
alternative intervention strategy in the face of a ZIKV outbreak.
Materials and Methods
Cell Lines. Human embryonic kidney (HEK) 293-6E cells were cultured at 37 °C
in 8% CO2, shaking at 120 rpm. The other cell lines were cultured at 37 °C in
5% CO2, without shaking: human hepatocyte (Huh)-7.5 cells were grown in
Dulbecco’s modified Eagle medium (DMEM) supplemented with 1% non-
essential amino acids (NEAAs) and 5% fetal bovine serum (FBS); human
Lenti-X 293T cells were grown in DMEM supplemented with 10% FBS.
Antibodies. The human IgG1 antibodies Z004 and Z021 and their Fc variants
(GRLR and GRLR/LS) were previously described (23, 30). Z004GRLR and
Z021GRLR were prepared by transient transfection of mammalian HEK 293-6E
cells with equal amounts of Ig heavy and light chain expression vectors. The
supernatant was harvested after 7 d and the antibodies were purified using
Protein G Sepharose 4 Fast Flow. Lipopolysaccharide (LPS) was removed with
Triton X-114 and the antibodies concentrated in phosphate-buffered saline
(PBS). Z004GRLR/LS (TDI-Y-001) and Z021GRLR/LS (TDI-Y-002) were produced by
WuXi Biologics and provided by the Tri-Institutional Therapeutics Discovery In-
stitute (TDI). In TDI-Y-002, the Z021 heavy chain variable sequence was modified
(C50V).
Macaque Infection Experiments.
Animals and care. All rhesus macaques (Macaca mulatta) in the study were of
Indian origin and were born and raised in the conventional (i.e., not specific
pathogen free) breeding colony at the California National Primate Research
Center (CNPRC) (SI Appendix, Table S4). While none of the animals were posi-
tive for type D retrovirus, simian immunodeficiency virus (SIV), or simian lym-
phocyte tropic virus type 1, two animals in the pregnancy control group (C02
and C07) were seropositive for West Nile virus due to prior outdoor housing. All
animals in the pregnancy experiment had prior pregnancies (range 2 to 10).
The CNPRC is accredited by the Association for Assessment and Accredi-
tation of Laboratory Animal Care International (AAALAC). Animal care was
performed in compliance with the 2011 Guide for the Care and Use of
Laboratory Animals provided by the Institute for Laboratory Animal Re-
search. Macaques were housed indoor in stainless steel cages (Lab Product,
Inc.) whose sizing was scaled to the size of each animal, as per national
standards, and were exposed to a 12-h light/dark cycle, 64 to 84° F, and 30 to
70% room humidity. Animals had free access to water and received com-
mercial chow (high protein diet, Ralston Purina Co.) and fresh produce
supplements. The study was approved by the Institutional Animal Care and
Use Committee of the University of California, Davis.
Experiments with nonpregnant macaques. All 18 rhesus macaques (M.
mulatta) were healthy juvenile males and females (∼2 to 4 y of age). When
necessary for inoculations or sample collections, macaques were immobi-
lized with 10 mg/kg ketamine hydrochloride (Parke-Davis) injected in-
tramuscularly after overnight fasting. Z004 and Z021 antibodies were
administered by i.v. route to macaques at doses of 15 mg/kg body weight 24
h before s.c. inoculation with Puerto Rican ZIKV (ZIKV-PR; 103 PFU, strain
PRVABC-59; GenBank KU501215). For the experiments in SI Appendix, Fig.
S2, two macaques were administered antibody Z021 (with wild-type Fc) and
infected i.v. with high dose of Brazilian ZIKV (ZIKV-BR; 105 PFU, strain
SPH2015; GenBank KU321639.1) similar to previously reported (23). Ma-
caques were evaluated at least daily for clinical signs of disease, including
poor appetence, stool quality, dehydration, diarrhea, and inactivity. None of
the animals that received the antibodies developed any clinical signs, sug-
gesting a good safety profile. Animals were sedated for antibody adminis-
tration (minus 24 h), at time 0 (virus inoculation), daily for 7 to 8 d, and
then every few days for sample collection. Ethylenediaminetetraacetic acid
(EDTA) anti-coagulated blood samples were collected using venipuncture
and plasma was isolated. At the end of the study, animals were killed for
tissue collection. The samples were processed, and the viral RNA was mea-
sured from plasma and tissues as described below for pregnant macaques.
Experiments with pregnant macaques.
Time-mated breeding and pregnancy selection. For time-mated breeding, the
female macaques were monitored for reproductive cycle and at the time of
optimal receptiveness, temporarily housed with breeding males to induce
pregnancy. Gestational ages were determined from the menstrual cycle of
the dam and the fetus length at initial ultrasound compared to growth data
in the CNPRC rhesus macaque colony. Fetal health and viability were
rechecked via ultrasound immediately before the first ZIKV inoculation
(∼GD30) and regularly thereafter.
Antibody treatment and virus inoculations. Z004 and Z021 antibodies were
administered to macaques by i.v. route at doses of 15 mg/kg body weight each
by 24 h before each virus inoculation. Each pregnant animal was inoculated
with virus three times.Whereas the normal gestation of rhesusmacaques is 165
d, inoculations occurred at approximately GD30, 60, and 90, corresponding to
first and second trimester of humangestation. TheGD30 andGD90 inoculations
were done with a 2015 Puerto Rico isolate (PRVABC-59; GenBank KU501215),
while theGD60 inoculationwasdonewith a 2015Brazil isolate (strain Zika virus/
H.sapiens-tc/BRA/2015/Brazil_SPH2015; GenBank KU321639.1), the same strain
as tested earlier in pregnant and nonpregnant animals (11, 27). The use of two
strains was intended to mimic an endemic area where different variants may
circulate. Aliquots of both virus stocks were kept frozen in liquid nitrogen, and
a new vial was thawed shortly before each inoculation. For each inoculation,
the inoculum was adjusted to 1,000 PFU in 0.5 mL of RPMI-1640 medium, then
kept on wet ice and injected s.c. to simulate the route of mosquito feeding.
This dose is higher than the typical dose received from a mosquito bite, which
in laboratory vector competence experiments with Californian Aedes aegypti
was ∼30 PFU for both the ZIKV isolates used in this study (39).
Sample collection and clinical observations and monitoring. Macaques were
evaluated twice daily for clinical signs of disease, including poor appetence,
stool quality, dehydration, diarrhea, and inactivity. When necessary, ma-
caques were immobilized with ketamine hydrochloride (Parke-Davis) at
10 mg/kg and injected intramuscularly after overnight fasting. Animals in both
the ZIKV-treated and placebo cohorts were sedated at days 0 (time of first
virus inoculation; approximately GD30), 2, 3, 5, 7, 14, 21, 30 (second ZIKV
inoculation at GD60), 32, 37, 44, 51, 60 (third ZIKV inoculation; GD90), 62, 67,
and then weekly until time of killing between GD155 and GD162, for sample
collection and ultrasound monitoring of fetal health. The antibody-treated
animals had additional time points of sedation for blood collection and IV
antibody administration 1 d before each ZIKV inoculation. EDTA anti-
coagulated blood was collected using venipuncture at every time point for
complete blood counts (with differential count), and a separate aliquot of
blood was centrifuged for 10 min at 800 × g to separate plasma from cells.
The plasma was spun an additional 10 min at 800 × g to further remove cells,
and aliquots were immediately frozen at −80 °C.
Ultrasound-guided amniocentesis was conducted starting at day 14 after
inoculation (GD44), and then at all time points listed above with exception
of days 32 and 62 after initial infection. The amniocentesis was conducted
using sterile techniques by inserting a 22-gauge, 1.5-inch spinal needle into
the amniotic sac. The fetal heart rate was obtained before and after am-
niocentesis. The area of umbilical entry through the amniotic sac was always
avoided to prevent damage to the umbilical arteries and vein. Whenever
possible, placental tissue was avoided during the collection of amniotic fluid.
Amniotic fluid was spun to remove cellular debris, and the supernatant was
aliquoted and immediately cryopreserved at −80 °C for viral RNA assays.
Necropsy and tissue collection. All necropsies were performed by a board-
certified anatomic pathologist and a pathology technician. For animals
that had early fetal loss, the procedures described below were performed to
the best extent possible based on fetal size. Hysterotomy was performed by a
veterinary surgeon on the pregnant macaques under inhalation anesthesia.
After collection of amniotic fluid and cord blood, the fetus was killed with an
overdose of sodium pentobarbital (≥120 mg/kg). Fetal and organ weights
were measured with a scale, and crown–rump length, biparietal diameter,
head height, head length, and femur length, were derived from caliper
measurements. A detailed tissue dissection was performed. Except for some
animals that had early fetal loss and were maintained several weeks after
removal of the fetus, all other mothers were killed shortly after their fetus
with an overdose of sodium pentobarbital for tissue collection.
Each tissue was grossly evaluated in situ, and then excised, with further
dissection with separate forceps and razor blades for each tissue to minimize
risks for cross-contamination. Tissues were collected for viral analyses in
RNAlater (according to manufacturer’s instructions); extra available samples
were snap frozen and stored at −70 °C. Tissues were also preserved in 10%
neutral-buffered formalin and routinely paraffin embedded, and slides were
created and routinely stained with hematoxylin and eosin (H&E).
Isolation and quantitation of viral RNA from fluids and tissues for determination
of infection status. ZIKV RNA was isolated from samples and measured in
triplicate by qRT-PCR according to methods described previously (27), mod-
ified to increase the initial volume of sample tested from 140 to 300 μL to
increase sensitivity. According to the volume available, the limit of detection
for plasma and amniotic fluid ranged from 1.5 to 2.3 log10 viral RNA copies
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per milliliter of fluid. RNAlater preserved tissues were homogenized to a
liquid state with glass beads (Fisher Scientific) or a 5-mm steel ball (Qiagen).
For tissues, the limit of detection (LOD) varied depending on the weight of
tissue sampled with a mean of 3.5 log10 RNA copies/g of tissue, determined
according to the calculations described in ref. 50.
Formaternal plasma, amniotic fluid, fetal cordblood, and fetal cerebrospinal
fluid, all samples from both control and vaccine group animals that could be
collected were tested. For the maternal tissue samples, as maternal infection
wasnot themain focus of this study, a limited selectionof lymphoid tissuesmost
likely to have viral RNA based on prior studies was tested (11, 27), with addition
of uterus due to proximity to the placenta and fetus. For the analysis of fetal
tissue samples for viral RNA, we started our analysis with the control fetuses
and tested 26 fetal and MFI tissues, consisting of tissues most likely to contain
viral RNA based on our prior study (11). Next we generated a heatmap and
selected a list of 17 tissues consisting of those most likely to be infected and
diagnosed the most infections in the control fetuses, with addition of brain
regions most likely to have histological lesions in the current study (such as
hippocampus), or found to be infected in human fetuses affected by CZS (51).
The criteria to define infection were used systematically for both control and
antibody-treated group fetuses: a fetus was considered ZIKV infected if at
least one tissue had a consistent qRT-PCR signal (3/3 replicates positive for viral
RNA); this situation applied to 11 of the 12 control fetuses. In a rare case, when
a fetus only had a sample with inconsistent qRT-PCR signal (1 out of 3 repli-
cates positive) while all other tissues were negative, retesting was performed,
generally on a different aliquot. If the retest result was negative (3/3 repli-
cates), the sample was considered not to contain detectable ZIKV RNA; if this
occurred for all tissues from a fetus, the fetus was considered not infected.
One control fetus (C07-F) and one antibody-group fetus (AB05-F) met these
criteria and were therefore considered uninfected.
Histopathology. Sections of fixed and embedded fetal tissueswere stainedwith
H&E and evaluated by a board-certified anatomic pathologist. Scoring of critical
fetal tissues was done according to criteria outlined in SI Appendix, Table S3.
Virus Sequencing. For the detection of virusmutations at the EDIII region, ZIKV
RNA was extracted at peak plasma viremia and Qiagen One-Step RT-PCR was
performed using either of two primer sets targeting sequences surrounding
the ZIKV EDIII region, as previously detailed (23). Due to low levels of viremia
in some samples, reliable EDIII sequence information was not always
obtained in samples with amounts below 103 RNA copies/mL plasma. Mu-
tations reported are based on changes in the majority nucleotide in se-
quencing chromatograms; concordant sequences in both directions were
used to identify mutations.
Reporter Virus Particles. Luciferase encoding RVPs bearing the wild-type or
mutant ZIKV E proteins of interest were produced by cotransfection of Lenti-
X-293T cells with plasmid pWNVII-Rep-REN-IB (WNV replicon expression
construct; ref. 52) in combination with plasmids expressing flavivirus CprME
(1 μg of pWNVII-Rep-REN-IB and 3 μg of the CprME plasmid) as previously
detailed (30).
The plasmids for expression of wild-type ZIKV CprME with E protein se-
quence corresponding to Puerto Rican ZIKV (strain PRVABC59) that was used in
this study was generated from plasmid pZIKV/HPF/CprM*E* (30) by replacing a
BspHI/SacII fragment with sequences corresponding to the PRVABC59 strain
that were generated by PCR using oligos RU-O-24379 and RU-O-24380- and
PRVABC59-derived cDNA as template. The resulting plasmid was designated
pZIKV/HPF/CprM*PRVABC59E*. Assembly PCR-based site-directed mutagenesis
was then used to introduce in pZIKV/HPF/CprM*PRVABC59E* the V330L,
T309A, V330L/T309A, and V330L/T309I mutations that resulted in plasmids
pZIKV/HPF/CprM*PRVABC59E* (V330L), pZIKV/HPF/CprM*PRVABC59E* (T309A),
pZIKV/HPF/CprM*PRVABC59E* (V330L/T309A), and pZIKV/HPF/CprM*PRVABC59E*
(V330L/T309I). Similarly, the ZIKV RVPs encoding for the T335 mutations (SI
Appendix, Fig. S2) were generated by modifying plasmid pZIKV/HPF/
CprM*E* (30) to introduce the T335A and T335I modifications resulting in
pZIKV/HPF/CprM*E* (T335A) and pZIKV/HPF/CprM*E* (T335I), respectively. The
primers used for assembly PCR and mutagenesis are listed in SI Appendix,
Table S5. All PCR-derived plasmid regions were verified by sequencing.
In Vitro Neutralization Assay. RVP neutralization of luciferase-encoding RVPs
by antibodies was performedwith Huh-7.5 cells in 96-well plates, in triplicate,
as previously detailed (30), and the luciferase activity was read using a
FLUOstar Omega luminometer (BMG LabTech). The neutralization capacity
of the antibodies against wild-type or mutant RVPs was determined by the
percentage of luciferase activity obtained relative to RVPs incubated with
isotype control antibody 10-1074 (53). Representatives of at least two in-
dependent experiments are shown.
Measurements of Human IgG in Macaque Plasma. ELISA was used for the
detection of human IgG as previously detailed (30). Briefly, the biotinylated
anti-human IgG capture antibody was added to neutravidin-coated 96-well
plates. Upon washes, the plates were blocked with 2% bovine serum albu-
min (BSA), blotted, and then serial dilutions of the macaque plasma were
added to the wells (5 steps of 1:4 dilutions in PBS-T, starting with 1:10). Each
plate included serial dilutions of the standard, in duplicates (Z004 IgG, 11
steps of 1:3 dilutions in PBS-T, starting with 10 μg/mL). Plates were incubated
for 1 h at room temperature and washed prior to adding the detection re-
agent anti-human IgG-horseradish peroxidase (HRP). After washes, the re-
action was developed with 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic
acid (ABTS) substrate (Life Technologies).
Measurements of Human IgG in Mouse Serum. ELISA was used for the detection
of human IgG as previously detailed (54). Briefly, FcRn/FcγR-humanized mice
were injected i.v. with 100 μg of Z004 or Z021 Fc variants. High-binding 96-well
microtiter plates (Nunc) were coated overnight at 4 °C with neutravidin. All
sequential steps were performed at room temperature. Plates were blocked
for 1 h with PBS/2% BSA and incubated with biotinylated goat anti-human IgG
antibodies for 1 h (5 μg/mL; catalog 109-066-170, Jackson ImmunoResearch).
Serum samples were serially diluted and incubated for 1 h, followed by in-
cubation with HRP-conjugated anti-human IgG. After washes, the reaction was
developed with the 3,3′,5,5′-tetramethylbenzidine (TMB) peroxidase substrate
system (KPL) and stopped with 2 M phosphoric acid. Αbsorbance at 450 nm
was immediately recorded using a SpectraMax Plus spectrophotometer (Mo-
lecular Devices), background absorbance from negative control samples was
subtracted, and duplicate wells were averaged.
Statistical Analyses. Statistical analyses were performed with Prism 8
(GraphPad).
Data Availability. All data are available in SI Appendix.
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